Table 1 Descriptive characteristics of rheumatoid arthritis patients during first bDMARD or tsDMARD use
|  | Total | TNFα inhibitor | Non-TNFα inhibitor | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Etanercept | Infliximab | Adalimumab | Golimumab | Tocilizumab | Rituximab | Tofacitinib | Abatacept |
Number of participants, N (%) | 11,720 | 2680 (22.9) | 1315 (11.2) | 3229 (27.6) | 1197 (10.2) | 1378 (11.8) | 67 (0.6) | 701 (6.0) | 1153 (9.8) |
Age, years, median (IQR) | 56 (47–64) | 55 (45–64) | 56 (48–63) | 54 (44–62) | 55 (46–64) | 57 (49–65) | 60 (50–67) | 56 (47–63) | 60 (52–68) |
Sex, N (%) | |||||||||
 Men | 2152 (18.4) | 518 (19.3) | 217 (16.5) | 581 (18.0) | 216 (18.0) | 253 (18.4) | 11 (16.4) | 128 (18.3) | 228 (19.8) |
 Women | 9568 (81.6) | 2162 (80.7) | 1098 (83.5) | 2648 (82.0) | 981 (82.0) | 1125 (81.6) | 56 (83.6) | 573 (81.7) | 925 (80.2) |
No. of csDMARD, N (%) | |||||||||
 ≤1 | 1790 (15.3) | 517 (19.3) | 133 (10.1) | 450 (13.9) | 150 (12.5) | 205 (14.9) | 26 (38.8) | 133 (19.0) | 176 (15.3) |
 2 | 5156 (44.0) | 1086 (40.5) | 590 (44.9) | 1378 (42.7) | 597 (49.9) | 666 (48.3) | 21 (31.3) | 337 (48.1) | 481 (41.7) |
 3 | 3586 (30.6) | 798 (29.8) | 437 (33.2) | 1046 (32.4) | 369 (30.8) | 372 (27.0) | 14 (20.9) | 180 (25.7) | 370 (32.1) |
 ≥4 | 1188 (10.1) | 279 (10.4) | 155 (11.8) | 355 (11.0) | 81 (6.8) | 135 (9.8) | 6 (9.0) | 51 (7.3) | 126 (10.9) |
Steroids use, mg/day, median (IQR) | 4.5 (2.8–6.2) | 4.7 (2.9–6.3) | 3.9 (2.5–5.9) | 4.7 (2.9–6.5) | 4.2 (2.5–6.0) | 4.1 (2.6–6.0) | 4.3 (3.3–6.4) | 3.9 (2.5–6.1) | 4.8 (3.2–6.4) |
Enrollment year, N (%) | |||||||||
 2011 | 1060 (9.0) | 421 (15.7) | 161 (12.2) | 450 (13.9) | 0 (0) | 0 (0) | 25 (37.3) | 0 (0) | 3 (0.3) |
 2012 | 1381 (11.8) | 547 (20.4) | 167 (12.7) | 641 (19.9) | 0 (0) | 0 (0) | 17 (25.4) | 0 (0) | 9 (0.8) |
 2013 | 1294 (11.0) | 466 (17.4) | 219 (16.7) | 488 (15.1) | 68 (5.7) | 29 (2.1) | 9 (13.4) | 0 (0) | 15 (1.3) |
 2014 | 1822 (15.5) | 387 (14.4) | 284 (21.6) | 386 (12.0) | 239 (20.0) | 263 (19.1) | 2 (3.0) | 0 (0) | 261 (22.6) |
 2015 | 1393 (11.9) | 237 (8.8) | 165 (12.5) | 268 (8.3) | 228 (19.0) | 246 (17.9) | 3 (4.5) | 2 (0.3) | 244 (21.2) |
 2016 | 1388 (11.8) | 183 (6.8) | 122 (9.3) | 351 (10.9) | 212 (17.7) | 274 (19.9) | 4 (6.0) | 7 (1.0) | 235 (20.4) |
 2017 | 1458 (12.4) | 181 (6.8) | 90 (6.8) | 312 (9.7) | 232 (19.4) | 287 (20.8) | 3 (4.5) | 171 (24.4) | 182 (15.8) |
 2018 | 1765 (15.1) | 239 (8.9) | 101 (7.7) | 304 (9.4) | 205 (17.1) | 245 (17.8) | 4 (6.0) | 485 (69.2) | 182 (15.8) |
 2019 | 159 (1.4) | 19 (0.7) | 6 (0.5) | 29 (0.9) | 13 (1.1) | 34 (2.5) | 0 (0) | 36 (5.1) | 22 (1.9) |
CCI, N (%) | |||||||||
 1–2 | 5080 (43.3) | 1239 (46.2) | 614 (46.7) | 1635 (50.6) | 481 (40.2) | 492 (35.7) | 24 (35.8) | 244 (34.8) | 351 (30.4) |
 3–4 | 4125 (35.2) | 902 (33.7) | 462 (35.1) | 1050 (32.5) | 429 (35.8) | 540 (39.2) | 16 (23.9) | 275 (39.2) | 451 (39.1) |
 ≥5 | 2515 (21.5) | 539 (20.1) | 239 (18.2) | 544 (16.8) | 287 (24.0) | 346 (25.1) | 27 (40.3) | 182 (26.0) | 351 (30.4) |
FU duration, year, median (IQR) | 2.7 (0.8–5.7) | 5.4 (1.7–6.7) | 4.0 (1.1–6.1) | 4.8 (1.1–6.5) | 1.4 (0.5–3.1) | 1.8 (0.7–3.1) | 6.4 (5.3–7.5) | 0.6 (0.3–1.0) | 1.7 (0.6–3.3) |